255 related articles for article (PubMed ID: 33578756)
1. HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery.
Chytil P; Kostka L; Etrych T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33578756
[TBL] [Abstract][Full Text] [Related]
2. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release.
Chytil P; Koziolová E; Etrych T; Ulbrich K
Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28805040
[TBL] [Abstract][Full Text] [Related]
3. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines Meet Disordered Proteins: A Shift from Traditional Materials and Concepts to Innovative Polymers.
Rizzuti B
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294800
[TBL] [Abstract][Full Text] [Related]
5. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
6. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.
Duncan R; Vicent MJ
Adv Drug Deliv Rev; 2010 Feb; 62(2):272-82. PubMed ID: 20005271
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting.
Lomkova EA; Chytil P; Janoušková O; Mueller T; Lucas H; Filippov SK; Trhlíková O; Aleshunin PA; Skorik YA; Ulbrich K; Etrych T
Biomacromolecules; 2016 Nov; 17(11):3493-3507. PubMed ID: 27636143
[TBL] [Abstract][Full Text] [Related]
8. Designing polymer conjugates as lysosomotropic nanomedicines.
Duncan R
Biochem Soc Trans; 2007 Feb; 35(Pt 1):56-60. PubMed ID: 17233601
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment.
Noack AK; Lucas H; Chytil P; Etrych T; Mäder K; Mueller T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825790
[TBL] [Abstract][Full Text] [Related]
10. Polymer nanomedicines based on micelle-forming amphiphilic or water-soluble polymer-doxorubicin conjugates: Comparative study of in vitro and in vivo properties related to the polymer carrier structure, composition, and hydrodynamic properties.
Braunová A; Chytil P; Laga R; Šírová M; Machová D; Parnica J; Říhová B; Janoušková O; Etrych T
J Control Release; 2020 May; 321():718-733. PubMed ID: 32142741
[TBL] [Abstract][Full Text] [Related]
11. Structural and chemical aspects of HPMA copolymers as drug carriers.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2010 Feb; 62(2):150-66. PubMed ID: 19931329
[TBL] [Abstract][Full Text] [Related]
12. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
13. Long-term biodistribution study of HPMA-ran-LMA copolymers in vivo by means of
Wagener K; Moderegger D; Allmeroth M; Reibel A; Kramer S; Biesalski B; Bausbacher N; Zentel R; Thews O; Rösch F
Nucl Med Biol; 2018 Mar; 58():59-66. PubMed ID: 29413458
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
16. Tumor Stimulus-Responsive Biodegradable Diblock Copolymer Conjugates as Efficient Anti-Cancer Nanomedicines.
Šubr V; Pola R; Gao S; Islam R; Hirata T; Miyake D; Koshino K; Zhou JR; Yokomizo K; Fang J; Etrych T
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629120
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release.
Ferber S; Baabur-Cohen H; Blau R; Epshtein Y; Kisin-Finfer E; Redy O; Shabat D; Satchi-Fainaro R
Cancer Lett; 2014 Sep; 352(1):81-9. PubMed ID: 24614283
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
19. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
20. Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors.
Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E
PDA J Pharm Sci Technol; 2001; 55(3):191-201. PubMed ID: 11417110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
